Brown Rudnick to Provide IP Guidance to Navigator

Brown Rudnick will act as IP counsel to Navigator Medicines, a New Jersey-based biotech startup, following its $100 million Series A financing round.

Navigator announced the financing on Aug. 27. RA Capital Management and Forbion led the round.

The company will use the funds to support the development of NAV-240 and an OX40L-targeted portfolio from IMBiologics Corp. NAV-240 is a clinical-stage bispecific antibody against OX40L and TNFa, two clinically validated targets that are critical in the pathogenesis of several inflammatory diseases.

Founded in 2024 as a subsidiary of Sera Medicines, Navigator leads the advancement of biologics for targeted immune regulation and restoration. The company is committed to developing new therapies for patients living with complex, heterogenous autoimmune diseases.

Partner Adam Schoen leads the Brown Rudnick team, which includes associate Rob Ruh and patent agent Hugo Garrido.